Ole Thastrup
Founder bij 2CUREX AB
Profiel
Ole Thastrup is the founder of 2cureX ApS, where he holds the title of Director & Chief Scientific Officer since 2006.
He is also the founder of 2cureX AB, where he holds the title of Vice-Chairman since 2024.
Dr. Thastrup is also the founder of Noapab Holdings A..
Dr. Thastrup's current job(s) include Chief Executive Officer & Director at Ot311 ApS, Member at Novo Nordisk Fonden, and Head-Drug Design Department & Professor at the University of Copenhagen.
Dr. Thastrup's former job(s) include Principal at ZymoGenetics, Inc., Principal at Novo Nordisk A, and Head-Biosector at Carlsberg A from 2002 to 2006.
Actieve functies van Ole Thastrup
| Bedrijven | Functie | Begin |
|---|---|---|
| 2CUREX AB | Founder | 01-01-2006 |
2cureX ApS
 2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | Founder | 01-01-2006 |
| University of Copenhagen | Corporate Officer/Principal | - |
| Ot311 ApS | Chief Executive Officer | - |
Novo Nordisk Fonden
 Novo Nordisk Fonden Investment Trusts/Mutual FundsMiscellaneous Novo Nordisk Fonden provides basis for the commercial and research activities conducted by the companies. It also supports scientific and humanitarian purposes activities. It awards grants for research within biomedicine, biotechnology, general practice and family medicine, nursing, and art history at public research institutions. It bridges gap between the discoveries made by researchers in biomedicine and biotechnology and their commercial application. The company was founded by August Krogh, Marie Krogh, Harald Pedersen, Hans Christian Hagedorn, August Kongsted and Thorvald Pedersen in 1922 and is headquartered in Hellerup, Denmark. | Corporate Officer/Principal | - |
Eerdere bekende functies van Ole Thastrup
| Bedrijven | Functie | Einde |
|---|---|---|
| CARLSBERG A/S | Corporate Officer/Principal | 01-01-2006 |
| Noapab Holdings A/S | Chief Tech/Sci/R&D Officer | - |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| CARLSBERG A/S | Consumer Non-Durables |
| 2CUREX AB | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
Novo Nordisk Fonden
Novo Nordisk Fonden Investment Trusts/Mutual FundsMiscellaneous Novo Nordisk Fonden provides basis for the commercial and research activities conducted by the companies. It also supports scientific and humanitarian purposes activities. It awards grants for research within biomedicine, biotechnology, general practice and family medicine, nursing, and art history at public research institutions. It bridges gap between the discoveries made by researchers in biomedicine and biotechnology and their commercial application. The company was founded by August Krogh, Marie Krogh, Harald Pedersen, Hans Christian Hagedorn, August Kongsted and Thorvald Pedersen in 1922 and is headquartered in Hellerup, Denmark. | Miscellaneous |
| Noapab Holdings A/S | Commercial Services |
2cureX ApS
2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | Health Technology |
| Ot311 ApS |
